Mechanisms of progesterone receptor inhibition of inflammatory responses in cellular models of breast cancer

Molecular Endocrinology

Volumn 24, Issue 12, 2010, Pages 2292-2302

  Kobayashi, Sakiko ^a   Stice, James P ^a   Kazmin, Dmitri ^a   Wittmann, Bryan M ^a   Kimbrel, Erin A ^a   Edwards, Dean P ^b   Chang, Ching Yi ^a   McDonnell, Donald P ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FACTOR AF2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MIFEPRISTONE; ONAPRISTONE; PROGESTERONE RECEPTOR A; PROGESTERONE RECEPTOR B; PROMEGESTONE; TRANSCRIPTION FACTOR RELA;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CANCER MODEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; EPITHELIUM CELL; GENE CONTROL; GENETIC ANALYSIS; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN CONFORMATION; PROTEIN EXPRESSION; RECEPTOR AFFINITY; RECEPTOR BLOCKING; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

AMINO ACID SEQUENCE; CELL LINE; CELL LINE, TUMOR; ENHANCER ELEMENTS, GENETIC; EPITHELIAL CELLS; FEMALE; GONANES; HUMANS; INFLAMMATORY BREAST NEOPLASMS; INTERLEUKIN-1BETA; MIFEPRISTONE; MOLECULAR SEQUENCE DATA; NF-KAPPA B; PROGESTERONE; PROGESTINS; PROMOTER REGIONS, GENETIC; PROTEIN ISOFORMS; RECEPTORS, PROGESTERONE; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRANSCRIPTIONAL ACTIVATION; TRANSLOCATION, GENETIC;

EID: 78649397753     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2010-0289     Document Type: Article

References (33)

1. Romieu G, Maudelonde T, Ulmann A, Pujol H, Grenier J, Cavalie G, Khalaf S, Rochefort H 1987 The antiprogestin RU486 in advanced breast cancer: preliminary clinical trial. Bull Cancer 74:455-461
2. Robertson JF, Willsher PC, Winterbottom L, Blamey RW, Thorpe S 1999 Onapristone, a progesterone receptor antagonist, as first-line therapy in primary breast cancer. Eur J Cancer 35:214-218 (Pubitemid 29136770)
3. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J 2002 Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288:321-333
4. Musgrove EA, Hamilton JA, Lee CS, Sweeney KJ, Watts CK, Sutherland RL 1993 Growth factor, steroid, and steroid antagonist regulation of cyclin gene expression associated with changes in T-47D human breast cancer cell cycle progression. Mol Cell Biol 13:3577-3587
5. Wade HE, Kobayashi S, Eaton ML, Jansen MS, Lobenhofer EK, Lupien M, Geistlinger TR, Zhu W, Nevins JR, Brown M, Otteson DC, McDonnell DP 2010 Multimodal Regulation of E2F1 Gene Expression by Progestins. Mol Cell Biol 30:1866-1877
6. Liang Y, Besch-Williford C, Brekken RA, Hyder SM 2007 Progestin-dependent progression of human breast tumor xenografts: a novel model for evaluating antitumor therapeutics. Cancer Res 67:9929-9936
7. Vignon F, Bardon S, Chalbos D, Rochefort H 1983 Antiestrogenic effect of R5020, a synthetic progestin in human breast cancer cells in culture. J Clin Endocrinol Metab 56:1124-1130 (Pubitemid 13055104)
8. Kalkhoven E, Wissink S, van der Saag PT, van der Burg B 1996 Negative interaction between the RelA(p65) subunit of NF-κB and the progesterone receptor. J Biol Chem 271:6217-6224 (Pubitemid 26095429)
9. Condon JC, Hardy DB, Kovaric K, Mendelson CR 2006 Up-regulation of the progesterone receptor (PR)-C isoform in laboring myometrium by activation of nuclear factor-κB may contribute to the onset of labor through inhibition of PR function. Mol Endocrinol 20:764-775
10. Hardy DB, Janowski BA, Corey DR, Mendelson CR 2006 Progesterone receptor plays a major antiinflammatory role in human myometrial cells by antagonism of nuclear factor-κB activation of cyclooxygenase 2 expression. Mol Endocrinol 20:2724-2733
11. Hardy DB, Janowski BA, Chen CC, Mendelson CR 2008 Progesterone receptor inhibits aromatase and inflammatory response pathways in breast cancer cells via ligand-dependent and ligand-independent mechanisms. Mol Endocrinol 22:1812-1824
12. Cao Y, Karin M 2003 NF-κB in mammary gland development and breast cancer. J Mammary Gland Biol Neoplasia 8:215-223 (Pubitemid 38129943)
13. Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M 1995 Immunosuppression by glucocorticoids: inhibition of NF-κB activity through induction of IκB synthesis. Science 270:286-290
14. Wolter S, Doerrie A, Weber A, Schneider H, Hoffmann E, von der Ohe J, Bakiri L, Wagner EF, Resch K, Kracht M 2008 c-Jun controls histone modifications, NF-κB recruitment, and RNA polymerase II function to activate the ccl2 gene. Mol Cell Biol 28:4407-4423
15. Cvoro A, Tzagarakis-Foster C, Tatomer D, Paruthiyil S, Fox MS, Leitman DC 2006 Distinct roles of unliganded and liganded estrogen receptors in transcriptional repression. Mol Cell 21:555-564
16. Zhou Y, Ling EA, Dheen ST 2007 Dexamethasone suppresses monocyte chemoattractant protein-1 production via mitogen activated protein kinase phosphatase-1 dependent inhibition of Jun N-terminal kinase and p38 mitogen-activated protein kinase in activated rat microglia. J Neurochem 102:667-678
17. Abraham SM, Lawrence T, Kleiman A, Warden P, Medghalchi M, Tuckermann J, Saklatvala J, Clark AR 2006 Antiinflammatory effects of dexamethasone are partly dependent on induction of dual specificity phosphatase 1. J Exp Med 203:1883-1889 (Pubitemid 44188463)
18. Harant H, Eldershaw SA, Lindley IJ 2001 Human macrophage inflammatory protein-3α/CCL20/LARC/Exodus/SCYA20 is transcriptionally upregulated by tumor necrosis factor-α via a non-standard NF-κB site. FEBS Lett 509:439-445
19. Nissen RM, Yamamoto KR 2000 The glucocorticoid receptor inhibits NFκB by interfering with serine-2 phosphorylation of the RNA polymerase II carboxy-terminal domain. Genes Dev 14:2314-2329
20. Chang C, Norris JD, Grøn H, Paige LA, Hamilton PT, Kenan DJ, Fowlkes D, McDonnell DP 1999 Dissection of the LXXLL nuclear receptor-coactivator interaction motif using combinatorial peptide libraries: discovery of peptide antagonists of estrogen receptors α and β. Mol Cell Biol 19:8226-8239
21. Heery DM, Kalkhoven E, Hoare S, Parker MG 1997 A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature 387:733-736 (Pubitemid 27270617)
22. Heery DM, Hoare S, Hussain S, Parker MG, Sheppard H 2001 Core LXXLL motif sequences in CREB-binding protein, SRC1, and RIP140 define affinity and selectivity for steroid and retinoid receptors. J Biol Chem 276:6695-6702
23. Zschiedrich I, Hardeland U, Krones-Herzig A, Berriel Diaz M, Vegiopoulos A, Müggenburg J, Sombroek D, Hofmann TG, Zawatzky R, Yu X, Gretz N, Christian M, White R, Parker MG, Herzig S 2008 Coactivator function of RIP140 for NFκB/RelA-dependent cytokine gene expression. Blood 112:264-276
24. Rogatsky I, Luecke HF, Leitman DC, Yamamoto KR 2002 Alternate surfaces of transcriptional coregulator GRIP1 function in different glucocorticoid receptor activation and repression contexts. Proc Natl Acad Sci USA 99:16701-16706 (Pubitemid 36034036)
25. Luecke HF, Yamamoto KR 2005 The glucocorticoid receptor blocks P-TEFb recruitment by NFκB to effect promoter-specific transcriptional repression. Genes Dev 19:1116-1127
26. Lange CA 2008 Challenges to defining a role for progesterone in breast cancer. Steroids 73:914-921
27. Moore MR, Conover JL, Franks KM 2000 Progestin effects on long-term growth, death, and Bcl-xL in breast cancer cells. Biochem Biophys Res Commun 277:650-654
28. Boonyaratanakornkit V, McGowan E, Sherman L, Mancini MA, Cheskis BJ, Edwards DP 2007 The role of extranuclear signaling actions of progesterone receptor in mediating progesterone regulation of gene expression and the cell cycle. Mol Endocrinol 21:359-375
29. Bookout AL, Mangelsdorf DJ 2003 Quantitative real-time PCR protocol for analysis of nuclear receptor signaling pathways. Nucl Recept Signal 1:e012
30. Wittmann BM, Sherk A, McDonnell DP 2007 Definition of functionally important mechanistic differences among selective estrogen receptor down-regulators. Cancer Res 67:9549-9560
31. Clemm DL, Sherman L, Boonyaratanakornkit V, Schrader WT, Weigel NL, Edwards DP 2000 Differential hormone-dependent phosphorylation of progesterone receptor A and B forms revealed by a phosphoserine site-specific monoclonal antibody. Mol Endocrinol 14:52-65 (Pubitemid 32260327)
32. DuSell CD, Umetani M, Shaul PW, Mangelsdorf DJ, McDonnell DP 2008 27-hydroxycholesterol is an endogenous selective estrogen receptor modulator. Mol Endocrinol 22:65-77
33. Norris JD, Chang CY, Wittmann BM, Kunder RS, Cui H, Fan D, Joseph JD, McDonnell DP 2009 The homeodomain protein HOXB13 regulates the cellular response to androgens. Mol Cell 36:405-416